US00091E1091 - Common Stock - After market: 3.29 -0.07 (-2.08%)
NASDAQ:ABSI (2/7/2023, 7:22:04 PM)-0.05 (-1.47%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-09 2022-11-09/bmo | Earnings (Next) | N/A N/A |
Ins Owners | 7.57% | Inst Owners | 47.66% |
Market Cap | 310.45M | Shares | 92.39M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 73.85 |
IPO | 07-22 2021-07-22 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON
P: 13609491041.0
CEO: Sean McClain
Employees: 216
Website: https://www.absci.com/
VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced...
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced...
Here you can normally see the latest stock twits on ABSI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: